Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 5/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.39 |
| ▸ | PDE4A | P27815 | 4/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20456502 | 0.81 | ERN1 (0.42) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL20455985 | 0.79 | PDE4D (0.40) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL20455996 | 0.74 | CA1 (0.50) | — | |
| SCHEMBL20455932 | 0.72 | ALDH1A1 (0.40) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL13412905 | 0.70 | CA5A (0.57) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL28482991 | 0.70 | MAPT (0.43) | — | |
| SCHEMBL5797004 | 0.69 | PDE4B (0.44) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL15754345 | 0.69 | MAP4K4 (0.48) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL30362273 | 0.69 | MAP4K4 (0.48) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL14799165 | 0.69 | MAP4K4 (0.48) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014873-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD. (AU) | 2021-05-25 | — | — | US | disclosed |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-02-20 | — | — | US | disclosed |
| CN-110546133-A | Anti-fibrotic compounds | SHIRE HUMAN GENETIC THERAPIES | 2019-12-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014873-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, SMAD2 | PDE4D 3418/4885PDE4B 2017/4885PDE4A 1891/4885 |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, SMAD2 | PDE4D 3750/4885PDE4B 2696/4885PDE4A 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.